

Supplementary Information for

Kappa chain maturation helps drive rapid development of an infant HIV-1 broadly neutralizing antibody lineage

Cassandra A Simonich^{1,2†}, Laura Doepker^{1†}, Duncan Ralph³, James A Williams⁴, Amrit Dhar^{3,5}, Zak Yaffe², Lauren Gentles^{6,7}, Christopher T Small³, Brian Oliver⁸, Vladimir Vigdorovich⁸, Vidya Mangala Prasad⁴, Ruth Nduati⁹, D Noah Sather⁸, Kelly K Lee⁴, Frederick A Matsen IV³, Julie Overbaugh^{1,2*}

¹Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

²Medical Scientist Training Program, University of Washington School of Medicine, Seattle, WA 98195, USA

³Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

⁴Department of Medicinal Chemistry, University of Washington, Seattle, WA 98195, USA

⁵Department of Statistics, University of Washington, Seattle, WA 98195, USA

⁶Department of Microbiology, University of Washington, Seattle, WA 98195, USA

⁷Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

⁸Center for Infectious Disease Research, Seattle, WA 98109, USA

⁹Department of Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya

*Corresponding author and lead contact: joverbau@fredhutch.org

†These authors contributed equally

Nature Communications, 2019

Supplementary Table 1

BF520 time point	Live PBMC count	PBMC viability	Replicate	Chain	Raw reads	Replicate-merged deduplicated sequences	BF520.1 lineage reads	Lineage overlap by replicates	BF520.1 lineage reads	Singlets	Doublets	Triplets	Multiplets (one sequence represented by each multiplicity value)
M9 (M6 pi)	7170000	93.14%	1	IgG	606016	355208	1126	0	584	576	7	1	0
			2	IgG	416253				542	541	1	0	0
			1	IgK	640947	823671	5174	0	2182	2058	99	19	4, 4, 5, 15, 26, 28
			2	IgK	1090670				2992	2902	70	15	4, 4, 4, 5, 10

Supplementary Table 1. BF520 next-generation sequencing results and BF520.1 mAb lineage summary.

Supplementary Table 2

% IGHV		% IGKV		% IGLV	
46.72	4-34*01	35.88	4-1*01	15.66	2-14*01+T165G
10.87	3-9*03	14.31	3-15*01	11.20	2-23*03
6.64	3-21*01	6.60	1-5*03	9.99	6-57*01
6.22	3-23*01	5.90	2-28*01	7.99	2-14*01+G156T
4.97	1-69*13	5.35	1-39*01	6.62	1-40*01
2.87	3-7*01	4.95	2D-29*02	5.10	2-11*01
2.38	4-39*01	4.79	3-11*01	5.00	2-8*01
2.31	4-38-2*01	4.55	3-20*01	4.48	8-61*01
1.63	1-2*02+G36A	2.88	2-30*02	4.37	4-69*01
1.36	3-74*01	2.13	1-12*01	4.14	3-25*02
1.31	5-51*01	1.96	1-33*01	3.63	3-10*01
1.21	2-5*01	1.42	1-9*01	3.40	9-49*01
1.02	3-33*01	1.22	1-NL1*01	3.12	1-47*01
0.98	7-4-1*02	1.15	6-21*01	2.59	1-44*01
0.94	1-18*01	1.00	1-13*02	2.34	3-21*03
0.94	1-2*02	0.75	3-15*01+T271C.A272G.A275G	2.08	3-1*01
0.82	1-46*01	0.72	3-11*01+C232A.A234G.G235C.C238T	1.51	7-46*01
0.81	1-24*01	0.54	1-8*01	1.33	1-51*01
0.68	4-59*08	0.54	1-NL1*01+T271C.A272T	1.04	5-45*01
0.58	1-8*02	0.44	1-27*01	0.94	7-43*01
0.57	3-48*01	0.41	1-6*01	0.80	3-27*01
0.53	3-15*01	0.36	1D-16*01	0.75	3-19*01
0.49	3-48*03	0.35	1-9*01+A222C.A243T.T264C	0.52	4-60*03
0.37	4-38-2*02	0.31	2D-29*02+A286G.G287C.A289C	0.40	10-54*01
0.33	3-30*07	0.28	1-17*03	0.23	2-14*01
0.33	1-69-2*01	0.27	1-16*02	0.21	1-36*01
0.32	3-53*01	0.27	5-2*01	0.13	5-39*01
0.30	3-49*04	0.19	2D-26*01	0.13	5-37*01
0.27	3-11*04	0.19	1-NL1*01+T264C	0.12	3-9*01
0.18	1-3*01	0.14	1D-8*01	0.10	2-18*02
0.18	2-70*10	0.13	1-17*01	0.07	5-52*01
0.17	3-72*01	-	-	-	-
0.16	4-31*03	-	-	-	-
0.14	1-58*02	-	-	-	-
0.13	4-4*07	-	-	-	-
0.09	4-4*02	-	-	-	-
0.09	3-20*01	-	-	-	-
0.07	3-64*01	-	-	-	-
% IGHD		% IGKD		% IGLD	
13.76	6-13*01	-	-	-	-
10.99	4-17*01	-	-	-	-
10.96	2-2*02	-	-	-	-
10.75	3-3*02	-	-	-	-
6.97	6-6*01	-	-	-	-
6.43	3-3*01	-	-	-	-
6.28	2-2*01	-	-	-	-
6.03	3-10*01	-	-	-	-
4.39	3-10*02	-	-	-	-
3.66	1-26*01	-	-	-	-
3.12	3-22*01	-	-	-	-
2.75	6-19*01	-	-	-	-
2.24	5-18*01	-	-	-	-
1.85	1-1*01	-	-	-	-
1.73	5-12*01	-	-	-	-
1.62	7-27*01	-	-	-	-
1.30	2-15*01	-	-	-	-
1.20	3-16*02	-	-	-	-
0.90	2-21*02	-	-	-	-
0.88	1-7*01	-	-	-	-
0.56	3-9*01	-	-	-	-
0.39	6-25*01	-	-	-	-
0.33	2-8*01	-	-	-	-
0.32	2-8*02	-	-	-	-
0.31	3-16*01	-	-	-	-
0.28	1-20*01	-	-	-	-
% IGHV		% IGKV		% IGLV	
72.86	4*02	34.72	1*01	55.94	3*02
11.47	1*01	24.26	2*01	39.20	2*01
6.27	3*02	23.17	4*01	3.84	1*01
3.56	5*02	10.70	3*01	1.03	7*01
2.40	2*01	7.15	5*01	-	-
2.37	6*02	-	-	-	-
1.07	6*03	-	-	-	-
% IGHD		% IGKD		% IGLD	
13.76	6-13*01	-	-	-	-
10.99	4-17*01	-	-	-	-
10.96	2-2*02	-	-	-	-
10.75	3-3*02	-	-	-	-
6.97	6-6*01	-	-	-	-
6.43	3-3*01	-	-	-	-
6.28	2-2*01	-	-	-	-
6.03	3-10*01	-	-	-	-
4.39	3-10*02	-	-	-	-
3.66	1-26*01	-	-	-	-
3.12	3-22*01	-	-	-	-
2.75	6-19*01	-	-	-	-
2.24	5-18*01	-	-	-	-
1.85	1-1*01	-	-	-	-
1.73	5-12*01	-	-	-	-
1.62	7-27*01	-	-	-	-
1.30	2-15*01	-	-	-	-
1.20	3-16*02	-	-	-	-
0.90	2-21*02	-	-	-	-
0.88	1-7*01	-	-	-	-
0.56	3-9*01	-	-	-	-
0.39	6-25*01	-	-	-	-
0.33	2-8*01	-	-	-	-
0.32	2-8*02	-	-	-	-
0.31	3-16*01	-	-	-	-
0.28	1-20*01	-	-	-	-
% IGHV		% IGKV		% IGLV	
72.86	4*02	34.72	1*01	55.94	3*02
11.47	1*01	24.26	2*01	39.20	2*01
6.27	3*02	23.17	4*01	3.84	1*01
3.56	5*02	10.70	3*01	1.03	7*01
2.40	2*01	7.15	5*01	-	-
2.37	6*02	-	-	-	-
1.07	6*03	-	-	-	-


Supplementary Table 2. BF520 inferred Ig germline genes. Shown with percent prevalence for IgM, IgK, and IgL. Newly inferred alleles are indicated by a plus sign, and the point mutations separating each from its nearest known counterpart. This inference was performed only for V, and not for D or J genes. Alleles corresponding to the BF520.1 antibody are highlighted in red.

Supplementary Fig. 1

a

BEAST (N=758)	ASR Probability < 0.8	ASR Probability >= 0.8	P(high-confidence ASR sequences on True Lineage)
Is ASR sequence off True Lineage?	0.89	0.0026	0.97
Is ASR sequence on True Lineage?	0.0092	0.095	
DNAML (N=90)	ASR Probability < 0.8	ASR Probability >= 0.8	P(high-confidence ASR sequences on True Lineage)
Is ASR sequence off True Lineage?	0	0.12	0.87
Is ASR sequence on True Lineage?	0.044	0.83	
DNAPARS (N=88)	ASR Probability < 0.8	ASR Probability >= 0.8	P(high-confidence ASR sequences on True Lineage)
Is ASR sequence off True Lineage?	0	0.1	0.89
Is ASR sequence on True Lineage?	0.057	0.84	
RevBayes (N=1052)	ASR Probability < 0.8	ASR Probability >= 0.8	P(high-confidence ASR sequences on True Lineage)
Is ASR sequence off True Lineage?	0.92	0.0029	0.96
Is ASR sequence on True Lineage?	0.0076	0.067	

b



Supplementary Fig. 1: Accuracy of Bayesian lineage reconstruction for BF520.1-like simulated sequence alignments. **a**, Comparison of BEAST, dnaml, dnapars, and RevBayes methods for antibody lineage reconstruction based on simulated antibody phylogenies. True Lineages were defined as the naïve-to-seed lineages on simulated clonal family trees. **b**, Comparison of the root-to-tip branch length distance distribution for the BF520.1 clonal family (in black) against the corresponding distributions for 10 independently simulated clonal families (in lighter colors), showing concordance between the simulations and the observed distribution. To compute the distribution for the BF520.1 family, we obtained 10,000 independent tree samples from RevBayes and computed the median root-to-tip branch length distance for each sequence in the clonal family. Each of the 10 simulated clonal families were obtained using the same simulation parameters. ASR: ancestral sequence reconstruction.

Supplementary Fig. 2

BF520.1 lineage heavy chain intermediates

a

Tier	Clade	VH	VK	naïve _{VH}	naïve _{VH}	Int1 _{VH}	Int2 _{VH}	Int3 _{VH}	Int4 _{VH}	Int5 _{VH}	Int6 _{VH}	mature _{VH}
				naïve _{VK}	mature _{VK}							
1A	B	SF162	>20	0.7	0.6	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6
		Q23.17	>20	1.1	2.2	0.9	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6
2	A	BG505.W6M.C2_T332N	>20	>20	>20	7.0	3.1	1.7	1.0	1.3	1.1	
		398F1	>20	5.5	4.9	3.7	1.3	0.6	<0.6	<0.6	<0.6	
		X2278	>20	19.5	>20	3.8	2.3	1.2	0.7	0.9	1.0	
	B	TRO.11	>20	>20	>20	>20	>20	6.5	4.8	7.9	5.9	
		BJOX002000	>20	>20	>20	15.8	3.4	1.0	0.8	1.3	0.9	
		CH119	>20	>20	>20	>20	14.7	6.1	3.7	6.1	6.0	
	C	CE1176	>20	17.0	17.9	13.5	8.7	6.1	5.6	7.0	5.1	
		QC406.F3	>20	<0.6	0.7	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6	
		CE0217	>20	>20	>20	>20	12.3	2.1	2.1	4.4	2.8	
		DU156.12	>20	>20	>20	16.9	9.8	2.0	1.8	2.3	2.2	
		DU422.1	>20	5.7	12.9	3.2	4.4	2.2	1.4	2.9	2.6	
		SIV	>20	>20	>20	>20	>20	>20	>20	>20	>20	


b

BF520.1 VH maximum likelihood lineage intermediates

Tier	Clade	VH	VK	naïve _{VH}	ML Int1 _{VH}	ML Int2 _{VH}	ML Int3 _{VH}	ML Int4 _{VH}	ML Int5 _{VH}	mature _{VH}
				mature _{VK}						
1A	B	SF162	0.7	0.7	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6
		Q23.17	1.1	2.0	3.6	1.2	<0.6	<0.6	<0.6	<0.6
2	A	BG505.W6M.C2_T332	>20	>20	>20	>20	6.3	2.5	1.1	1.1
		398F1	5.5	>20	>20	19.6	2.4	1.3	<0.6	<0.6
		X2278	19.5	18.8	19.9	7.1	2.8	1.3	1.0	1.0
	B	TRO.11	>20	>20	>20	>20	>20	15.3	5.9	5.9
		BJOX002000	>20	>20	>20	>20	11.9	2.8	0.9	0.9
		CH119	>20	>20	>20	>20	>20	8.8	6.0	6.0
	C	CE1176	17.0	>20	>20	>20	8.3	7.0	5.1	5.1
		QC406.F3	<0.6	<0.6	1.3	0.8	<0.6	<0.6	<0.6	<0.6
		CE0217	>20	>20	>20	>20	14.6	6.0	2.8	2.8

BF520.1 heavy chain (maximum likelihood)

c



d


BF520.1 VH parsimony lineage intermediates

Tier	Clade	VH	VK	naïve _{VH}	Pars Int1 _{VH}	Pars Int2 _{VH}	Pars Int3 _{VH}	Pars Int4 _{VH}	Pars Int5 _{VH} *	mature _{VH}
				mature _{VK}						
1A	B	SF162	0.7	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6
		Q23.17	1.1	0.9	1.4	1.2	<0.6	<0.6	<0.6	<0.6
2	A	BG505.W6M.C2_T332N	>20	>20	>20	>20	3.0	1.7	1.1	1.1
		398F1	5.5	5.2	15.7	11.7	1.4	0.6	<0.6	<0.6
		X2278	19.5	14.1	19.7	15.8	1.7	1.2	1.0	1.0
	B	TRO.11	>20	>20	>20	>20	15.1	6.5	5.9	5.9
		BJOX002000	>20	>20	>20	>20	3.1	1.0	0.9	0.9
		CH119	>20	>20	>20	>20	10.6	6.1	6.0	6.0
	C	CE1176	17.0	17.9	>20	>20	6.3	6.1	5.1	5.1
		QC406.F3	<0.6	<0.6	0.7	0.9	<0.6	<0.6	<0.6	<0.6
		CE0217	>20	>20	>20	>20	11.6	2.1	2.8	2.8

* same mAb as the Bayesian lineage VH Int4

BF520.1 heavy chain (parsimony)

e



Supplementary Fig. 2: Development of heterologous neutralization by the maturing BF520.1 heavy chain lineage. a,b,d, mAb neutralization of panel viruses by BF520.1 inferred Bayesian (a), Maximum likelihood (b), and Parsimony (d) lineage heavy chains paired with the mature kappa light chain. The top rows of the tables (VH and VK) show the origin of the antibody chain sequence used indicated by Int#_{VH} with # indicating the progression of intermediates in the lineage. These were paired with the indicated kappa chain, in most cases the mature kappa chain (mature_{VK}). Panel viruses are shown to the left, with the tier, clade and name indicated. IC₅₀ values (µg ml⁻¹) represent an average of two to three independent experiments performed in duplicate. IC₅₀ values are color-coded with darker shades indicating more potent neutralization. Grey indicates that 50% neutralization was not achieved at the highest mAb concentration tested. **c,e,** Amino acid alignments of maximum likelihood (c) and parsimony (e) heavy chain lineage intermediates.

Supplementary Fig. 3: Development of heterologous neutralization by the maturing BF520.1 kappa light chain lineage. a,b,d, mAb neutralization of panel viruses by BF520.1 inferred Bayesian (a), Maximum likelihood (b), and Parsimony (d) lineage kappa light chains paired with the mature heavy chain. Layout and details are as described for Supplementary Fig. 2. **c,e,** Amino acid alignments of maximum likelihood (c) and parsimony (e) kappa light chain lineage intermediates.

Supplementary Fig. 3

a

Tier	Clade	VH	mature _{VH}									
			naive _{VH}	naive _{VK}	Int1 _{VK}	Int2 _{VK}	Int3 _{VK}	Int4 _{VK}	Int5 _{VK}	Int6 _{VK}	Int7 _{VK}	mature _{VK}
1A	B	SF162	>20	1.1	0.9	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6
1B		Q23.17	>20	>20	>20	1.0	<0.6	0.7	0.7	<0.6	<0.6	<0.6
2	A	BG505.W6M.C2_T332N	>20	>20	>20	18.7	3.2	2.2	1.6	1.0	1.3	1.1
		398F1	>20	>20	>20	10.3	1.7	1.5	1.0	0.7	<0.6	<0.6
		X2278	>20	>20	>20	11.7	2.5	1.4	1.1	0.9	0.9	1.0
	B	TRO.11	>20	>20	>20	>20	>20	>20	14.6	7.0	8.0	5.9
		BJOX002000	>20	>20	>20	>20	5.7	3.5	1.6	0.8	1.1	0.9
	BC	CH119	>20	>20	>20	>20	>20	18.3	8.8	5.2	4.5	6.0
		CE1176	>20	>20	>20	15.0	8.2	6.9	6.3	5.3	5.6	5.1
		QC406.F3	>20	>20	>20	1.1	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6
		CE0217	>20	>20	>20	>20	>20	>20	6.4	3.1	4.7	2.8
		DU156.12	>20	>20	>20	>20	>20	15.7	3.7	0.9	2.1	2.2
	C	DU422.1	>20	>20	>20	11.0	5.1	5.4	5.2	3.9	4.3	2.6
		SIV	>20	>20	>20	>20	>20	>20	>20	>20	>20	>20

b


BF520.1 VK maximum likelihood lineage intermediates

Tier	Clade	VH	mature _{VH}						
			naive _{VK}	ML Int1 _{VK} *	ML Int2 _{VK} **	ML Int3 _{VK}	ML Int4 _{VK}	ML Int5 _{VK} ***	mature _{VK}
1A	B	SF162	1.1	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6
1B		Q23.17	>20	>20	4.8	1.7	<0.6	0.7	<0.6
2	A	BG505.W6M.C2_T332N	>20	>20	>20	>20	2.0	2.2	1.1
		398F1	>20	>20	>20	>20	1.4	2.4	<0.6
		X2278	>20	>20	>20	>20	2.8	2.9	1.0
	B	TRO.11	>20	>20	>20	>20	>20	>20	5.9
		BJOX002000	>20	>20	>20	>20	5.3	5.5	0.9
	BC	CH119	>20	>20	>20	>20	12.9	>20	6.0
		CE1176	>20	>20	>20	>20	6.2	7.3	5.1
		QC406.F3	>20	19.7	17.2	7.5	<0.6	<0.6	<0.6
		CE0217	>20	>20	>20	>20	>20	>20	2.8

* same mAb as Pars Int1_{VK}

** same mAb as Pars Int2_{VK}

*** same mAb as Pars Int6_{VK}



d


BF520.1 VK parsimony lineage intermediates

Tier	Clade	VH	mature _{VH}									
			naive _{VK}	Pars Int1 _{VK} *	Pars Int2 _{VK} **	Pars Int3 _{VK}	Pars Int4 _{VK}	Pars Int5 _{VK}	Pars Int6 _{VK} ***	Pars Int7 _{VK}	Pars Int8 _{VK}	mature _{VK}
1A	B	SF162	1.1	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6	
1B		Q23.17	>20	>20	4.8	2.3	17.6	<0.6	0.7	<0.6	<0.6	<0.6
2	A	BG505.W6M.C2_T332N	>20	>20	>20	>20	>20	1.7	2.2	2.4	0.7	1.1
		398F1	>20	>20	>20	>20	>20	2.1	2.4	1.9	0.8	<0.6
		X2278	>20	>20	>20	>20	>20	2.4	2.9	2.2	1.2	1.0
	B	TRO.11	>20	>20	>20	>20	>20	>20	>20	16.0	5.9	
		BJOX002000	>20	>20	>20	>20	>20	3.7	5.5	2.8	0.8	0.9
	BC	CH119	>20	>20	>20	>20	>20	>20	>20	12.6	4.1	6.0
		CE1176	>20	>20	>20	>20	>20	6.7	7.3	6.4	4.2	5.2
		QC406.F3	>20	19.7	17.2	8.0	18.5	<0.6	<0.6	<0.6	<0.6	<0.6
		CE0217	>20	>20	>20	>20	>20	>20	>20	>20	6.9	2.8

* same mAb as ML Int1_{VK}

** same mAb as ML Int2_{VK}

*** same mAb as ML Int5_{VK}



Supplementary Fig. 4

BF520.1 lineage paired intermediates

a

		VH	naive _{VH}	Int1 _{VH}	Int2 _{VH}	Int3 _{VH}	Int3 _{VH}	Int4 _{VH}	Int4 _{VH}	Int4 _{VH}	Int5 _{VH}	Int6 _{VH}	mature _{VH}	Minimal _{VH}
		% SHM	0.5	0.8	1.3	1.3	1.8	1.8	1.8	2.4	2.6	6.5	1.3	
		VK	naive _{VK}	Int1 _{VK}	Int2 _{VK}	Int3 _{VK}	Int4 _{VK}	Int4 _{VK}	Int5 _{VK}	Int6 _{VK}	Int7 _{VK}	mature _{VK}	Minimal _{VK}	
		% SHM	0.3	1.2	1.8	2.1	2.1	3.4	3.7	3.7	4.3	4.6	2.7	
1A	B	SF162	>20	>20	1.7	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6
1B		Q23.17	>20	>20	>20	2.1	1.2	<0.6	<0.6	<0.6	<0.6	0.7	<0.6	<0.6
2	A	BG505.W6M.C2_T332N	>20	>20	>20	>20	>20	6.2	2.1	1.4	1.0	1.6	1.1	1.3
		398F1	>20	>20	>20	>20	>20	2.0	1.2	<0.6	<0.6	0.8	<0.6	0.7
		X2278	>20	>20	>20	>20	>20	2.2	1.3	0.7	0.7	0.9	1.0	1.7
	B	TRO.11	>20	>20	>20	>20	>20	>20	18.9	10.3	6.0	6.7	5.9	14.2
		BJOX002000	>20	>20	>20	>20	>20	11.9	1.6	0.8	0.7	0.9	0.9	2.5
	C	CH119	>20	>20	>20	>20	>20	>20	8.2	4.4	3.0	5.7	6.0	16.0
		CE1176	>20	>20	>20	>20	>20	7.5	3.7	4.0	4.1	7.4	5.1	5.7
		QC406.F3	>20	>20	>20	3.1	1.1	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6
		CE0217	>20	>20	>20	>20	>20	>20	15.0	5.4	3.7	4.9	2.8	5.6
		DU156.12	>20	>20	>20	>20	>20	>20	4.1	2.2	2.0	2.2	2.2	14.8
	DU422.1	>20	>20	>20	10.3	8.2	2.8	2.9	2.3	1.5	4.1	2.6	2.6	
	SIV	>20	>20	>20	>20	>20	>20	>20	>20	>20	>20	>20	>20	>20

b

BF520.1 maximum likelihood lineage





		VH	ML Int1 _{VH}	ML Int3 _{VH}	ML Int4 _{VH}	ML Int5 _{VH}	mature _{VH}	%SHM
			1.0	2.1	0.8	1.3	6.5	
		VK	ML Int1 _{VK}	ML Int3 _{VK}	ML Int4 _{VK}	ML Int5 _{VK}	mature _{VK}	%SHM
			0.3	1.5	2.4	1.8	4.6	
1A	B	SF162	>20	15.9	<0.6	<0.6	<0.6	
1B		Q23.17	>20	>20	7.0	0.9	<0.6	
2	A	BG505.W6M.C2_T332N	>20	>20	>20	>20	1.1	
		398F1	>20	>20	>20	13.7	<0.6	
		X2278	>20	>20	>20	>20	1.0	
	B	TRO.11	>20	>20	>20	>20	5.9	
		BJOX002000	>20	>20	>20	>20	0.9	
	C	CH119	>20	>20	>20	>20	6.0	
		CE1176	>20	>20	>20	17.5	5.1	
		QC406.F3	>20	>20	7.4	1.8	<0.6	
		CE0217	>20	>20	>20	>20	2.8	

c



BF520.1 parsimony lineage

		VH	Pars Int1 _{VH}	Pars Int3 _{VH}	Pars Int4 _{VH}	Pars Int4 _{VH}	Pars Int4 _{VH}	Pars Int5 _{VH}	Pars Int5 _{VH}	Pars Int5 _{VH}	mature _{VH}	%SHM	
			0.5	0.8	1.3	1.3	1.3	1.8	1.8	1.8	6.5		
		VK	Pars Int1 _{VK}	Pars Int3 _{VK}	Pars Int4 _{VK}	Pars Int5 _{VK}	Pars Int6 _{VK}	Pars Int6 _{VK}	Pars Int7 _{VK}	Pars Int8 _{VK}	mature _{VK}	%SHM	
			0.3	1.2	1.5	2.1	1.8	1.8	2.4	3.0	4.6		
1A	B	SF162	>20	>20	13.9	<0.6	<0.6	<0.6	<0.6	<0.6	<0.6		
1B		Q23.17	>20	>20	>20	2.5	3.8	0.9	0.7	<0.6	<0.6		
2	A	BG505.W6M.C2_T332N	>20	>20	>20	>20	>20	13.1	6.8	1.5	1.1		
		398F1	>20	>20	>20	>20	19.6	2.6	2.1	0.8	<0.6		
		X2278	>20	>20	>20	>20	>20	8.9	3.7	1.2	1.0		
	B	TRO.11	>20	>20	>20	>20	>20	>20	>20	>20	5.9		
		BJOX002000	>20	>20	>20	>20	20.0	15.8	13.1	1.5	0.9		
	C	CH119	>20	>20	>20	>20	>20	>20	>20	>20	5.1	6.0	
		CE1176	>20	>20	>20	>20	>20	11.4	9.6	4.3	5.1		
		QC406.F3	>20	>20	>20	3.0	4.4	<0.6	<0.6	<0.6	<0.6		
		CE0217	>20	>20	>20	>20	>20	>20	>20	9.0	2.8		

Supplementary Fig. 4: Neutralization properties of paired VH and VK lineage intermediates. a,b,c, Neutralization of panel viruses by BF520.1 Bayesian (a), maximum likelihood (b) and parsimony (c) lineage heavy and light chain paired intermediates. IC₅₀ values in µg ml⁻¹. The top rows indicate the pairings of lineage intermediates for both VH and VK chains. Below each the % SHM in nucleotides is indicated. Layout and details are as described for Supplementary Fig. 2.






Correlation Corrected Unmasked Masked Phase Randomized



g

Fit	Molecule	Correlation
1	BF520.1	0.8513
2	BF520.1	0.6995
3	BF520.1	0.6991
4	BF520.1	0.6732



Supplementary Fig. 5: Data collection and refinement of BG505.SOSIP.664 in complex with BF520.1 Fab. **a**, A sample, frame aligned, micrograph illustrating particle density and distribution. **b**, Angular distribution plot generated in Relion/2.1. **c**, Local resolution analysis of the 4.8 Å cryo-EM reconstruction. The color key shown below indicates local resolution in Å. **d**, Fourier-shell correlation curves for correlation corrected (black), unmasked (green), masked (blue) and phase randomized (red). Dashed line represents the “gold-standard” FSC cutoff of 0.143. **e,f**, Densities corresponding to N332 and N301 glycans and positioning of glycans into the cryo-EM density. **g**, Correlation scores of the top fits for the BF520.1 Fab structure into the cryo-EM map. Scores were generated by Chimera UCSF fitmap command utilizing a global search. **h**, Positioning of gp41 HR2 -helix into the cryo-EM density. **i**, Best fit of BF520.1 homology model determined in (**h**). Shown are the variable light chain (left) and variable heavy chain (right). **j**, Positioning of the g41 HR1 -helix (left) and the gp120 1 helix into the cryo-EM density.

Supplementary Fig. 6

a

```

FR1          CDR1          FR2          CDR2          FR3
VH_Naive     QVQLVQSGAEVKKPGASVKVSKASGYTFTGYIMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFGQGRVTM
VH_Naive_2   -----R-----

FR3          CDR3          FR4
VH_Naive     TRDTSISTAYMELSRSLRSDDTAVIYCARGPFPNYIGPGSYWGQFDYWGQGLTVTVSS
VH_Naive_2   -----

```

b

```



FR1          CDR1          FR2          CDR2          FR3
VK_Naive     EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQKQKPGQAPRLLIYGASTRATGIPARF
VK_Naive_2   -----
VK_Naive_3   -----

FR3
VK_Naive     SGSGSGTEFTLTISLSQSEDFAVIYCQQYNNWPSPTFGPGTKVDIK
VK_Naive_2   -----M-----T-----
VK_Naive_3   -----M-----P-----

```

c

Tier	Clade		VH_Naive VK_Naive	VH_Naive_2 VK_Naive_2	VH_Naive_2 VK_Naive_3
1A	B	SF162	>20	>20	>20
		Q23.17	>20	>20	>20
2	A	BG505.W6M.C2_T332	>20	>20	>20
		398F1	>20	>20	>20
	B	X2278	>20	>20	>20
		TRO.11	>20	>20	>20
	BC	BJOX002000	>20	>20	>20
		CH119	>20	>20	>20
	C	CE1176	>20	>20	>20
		QC406.F3	>20	>20	>20
		CE0217	>20	>20	>20
	Autologous	A	BF520.W14M.E3	>20	>20
BF520.M6P.D1			>20	>20	>20
BF520.M6P.H1			>20	>20	>20
BF520.M6P.I1			>20	>20	>20
BF520.M6P.J1			>20	>20	>20




Supplementary Fig. 6: BF520.1 inferred naïve mAbs. **a,b**, Amino acid alignment of heavy chain (**a**) and kappa chain (**b**) inferred naïve sequences. **c**, BF520.1 naïve mAb neutralization of viruses. IC₅₀ values (µg ml⁻¹) are an average of two to three independent experiments performed in duplicate. Grey indicates that 50% neutralization was not achieved at the highest mAb concentration tested. **d**, mAb (analyte) binding to the BG505.SOSIP.664 (ligand) measured by BLI. 10E8 is a negative control as the SOSIP trimer does not contain the targeted MPER epitope. Data are representative of two independent experiments. **e**, mAb binding to HEp2A cells measured by ELISA (AESKULISA ANA-HEp-2; Aesku Diagnostics). The MPER-directed bnAb 4E10 is known to be autoreactive and was included as a positive control. VRC01 was included as a negative control. Data are representative of two independent experiments.

Supplementary Fig. 7

a

BF520.1 lineage binding to autologous HIV-1 Envs



b

	naïve _{VH}	Int1 _{VH}	Int2 _{VH}	Int3 _{VH}	Int3 _{VH}	Int4 _{VH}	Int4 _{VH}	Int4 _{VH}	Int5 _{VH}	Int6 _{VH}	mature _{VH}
	naïve _{VK}	Int1 _{VK}	Int2 _{VK}	Int3 _{VK}	Int4 _{VK}	Int4 _{VK}	Int5 _{VK}	Int6 _{VK}	Int6 _{VK}	Int7 _{VK}	mature _{VK}
BF520.W14M.E3	>20	>20	>20	>20	>20	>20	>20	>20	>20	>20	>20
BF520.M6P.D1	>20	>20	>20	>20	>20	>20	6.1	0.7	<0.6	<0.6	<0.6
BF520.M6P.H1	>20	>20	>20	>20	>20	>20	>20	11.6	4.6	2.3	1.4
BF520.M6P.I1	>20	>20	>20	>20	>20	5.8	2.1	1.1	0.7	1.6	1.1
BF520.M6P.J1	>20	>20	>20	>20	>20	>20	>20	3.6	1.8	1.7	1.8

Supplementary Fig. 7: Neutralization of autologous virus by BF520.1 paired lineage intermediates.

a, mAb binding to cell-surface Env detected by flow cytometry. VRC01 was a positive control for Env expression. The reported values have had background binding to mock-transfected cells subtracted. Data are representative of two independent experiments. **b**, The origin of the VH and VK chains are shown at the top and are described in Fig. 2b and 3d. Viruses tested are shown to the left and include a variant at first HIV detection (14 weeks of age) designated “W14” and four variants from ~2.2 months pi (6 months of age, “M6”). IC₅₀ values (µg ml⁻¹) are color coded with darker shading indicating greater neutralization potency. Results are an average of 2 independent experiments.